Roy Eldor

Summary

Publications

  1. pmc Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study
    Roy Eldor
    Diabetes Unit, Internal Medicine, Hadassah University Hospital, Jerusalem, Israel
    PLoS ONE 8:e59524. 2013
  2. doi request reprint Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues
    Roy Eldor
    Division of Diabetes and The Endocrinology Service, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Diabetes Metab Res Rev 28:85-9. 2012
  3. ncbi request reprint Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus
    Roy Eldor
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Int Rev Immunol 24:327-39. 2005
  4. doi request reprint Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results
    Roy Eldor
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
    Diabetes Metab Res Rev 25:316-20. 2009
  5. doi request reprint Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour
    Roy Eldor
    Endocrinology and Metabolism Service, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Clin Endocrinol (Oxf) 74:593-8. 2011
  6. pmc Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models
    Roy Eldor
    Diabetes Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    J Diabetes Sci Technol 4:1516-23. 2010
  7. pmc Inhibition of nuclear factor-κB activation in pancreatic β-cells has a protective effect on allogeneic pancreatic islet graft survival
    Roy Eldor
    Department of Endocrinology, Hadassah University Hospital, Jerusalem, Israel
    PLoS ONE 8:e56924. 2013
  8. doi request reprint Evaluation of impaired beta-cell function in nonobese-diabetic (NOD) mouse model using bioluminescence imaging
    Dror Sever
    Department of Endocrinology, Hadassah University Hospital, P O Box 12000, 91120 Jerusalem, Israel
    FASEB J 25:676-84. 2011
  9. ncbi request reprint Early use of insulin in type 2 diabetes
    Roy Eldor
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
    Diabetes Res Clin Pract 68:S30-5. 2005
  10. ncbi request reprint Immune modulation for prevention of type 1 diabetes mellitus
    Itamar Raz
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
    Trends Biotechnol 23:128-34. 2005

Collaborators

Detail Information

Publications15

  1. pmc Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study
    Roy Eldor
    Diabetes Unit, Internal Medicine, Hadassah University Hospital, Jerusalem, Israel
    PLoS ONE 8:e59524. 2013
    ..023), with a greater decrease during the early evening hours. In conclusion, ORMD-0801 oral insulin capsules in conjunction with subcutaneous insulin injections, well tolerated and effectively reduced glycemia throughout the day...
  2. doi request reprint Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues
    Roy Eldor
    Division of Diabetes and The Endocrinology Service, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Diabetes Metab Res Rev 28:85-9. 2012
    ..It is important to emphasize that regardless of it being a review of published evidence, it primarily represents the professional opinion of the writers...
  3. ncbi request reprint Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus
    Roy Eldor
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Int Rev Immunol 24:327-39. 2005
    ..Here we review the most promising therapies developed based on these targets and emphasize those that have reached human phase clinical investigation...
  4. doi request reprint Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results
    Roy Eldor
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
    Diabetes Metab Res Rev 25:316-20. 2009
    ....
  5. doi request reprint Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour
    Roy Eldor
    Endocrinology and Metabolism Service, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Clin Endocrinol (Oxf) 74:593-8. 2011
    ..Glucagonoma is a pancreatic neuroendocrine tumour that arises from alpha cells in the pancreas and is often accompanied by a characteristic clinical syndrome...
  6. pmc Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models
    Roy Eldor
    Diabetes Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    J Diabetes Sci Technol 4:1516-23. 2010
    ..To date, GLP-1 analogs are only available as injectable dosage forms, and its oral delivery is expected to provide physiological portal/peripheral concentration ratios while fostering patient compliance and adherence...
  7. pmc Inhibition of nuclear factor-κB activation in pancreatic β-cells has a protective effect on allogeneic pancreatic islet graft survival
    Roy Eldor
    Department of Endocrinology, Hadassah University Hospital, Jerusalem, Israel
    PLoS ONE 8:e56924. 2013
    ..Furthermore, we suggest a potential, readily available therapeutic agent that may temper this process...
  8. doi request reprint Evaluation of impaired beta-cell function in nonobese-diabetic (NOD) mouse model using bioluminescence imaging
    Dror Sever
    Department of Endocrinology, Hadassah University Hospital, P O Box 12000, 91120 Jerusalem, Israel
    FASEB J 25:676-84. 2011
    ....
  9. ncbi request reprint Early use of insulin in type 2 diabetes
    Roy Eldor
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
    Diabetes Res Clin Pract 68:S30-5. 2005
    ..This new approach, its rationale, benefits and misgivings are discussed in this review...
  10. ncbi request reprint Immune modulation for prevention of type 1 diabetes mellitus
    Itamar Raz
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
    Trends Biotechnol 23:128-34. 2005
    ..Here, we review the results of these trials...
  11. doi request reprint Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms
    Itamar Raz
    Diabetes Unit, Hadassah University Hospital, Jerusalem, Israel
    Diabetes Metab Res Rev 28:321-4. 2012
    ..Adherence to strict scientific methodology, ongoing large clinical trials and creating adjudicated patient databases may facilitate early recognition of adverse effects while avoiding disruptive false alarms...
  12. pmc Effect of short-term hyperglycemia on protein kinase C alpha activation in human erythrocytes
    Leonid Livshits
    The Diabetes Research Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Rev Diabet Stud 9:94-103. 2012
    ..Protein kinase C alpha (PKCα) is a major regulator of many metabolic processes and structural changes in erythrocytes, and may play a significant role in the development of hyperglycemia-mediated cellular abnormalities...
  13. doi request reprint The ToI-beta transgenic mouse: a model to study the specific role of NF-kappaB in beta-cells
    Roy Eldor
    Department of Endocrinology, Hadassah University Hospital, Jerusalem, Israel
    Diabetes Res Clin Pract 86:S7-14. 2009
    ..Together, our results show the ToI-beta mouse model to be a highly controlled and very accurate model for examining pancreatic beta-cell-specific temporal inhibition of NF-kappaB...
  14. pmc The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain
    Roy Eldor
    Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
    Rev Diabet Stud 6:6-12. 2009
    ..Using our newly suggested system, a physician will first calculate the adequate HbA1c goal for his patient and then choose the drug that will best suit him, thus tailoring the treatment to the patients needs...